Sagimet Biosciences Series Stock Alpha and Beta Analysis
| SGMT Stock | 3.76 0.19 4.81% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sagimet Biosciences Series. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sagimet Biosciences over a specified time horizon. Remember, high Sagimet Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sagimet Biosciences' market risk premium analysis include:
Beta (0.30) | Alpha (0.26) | Risk 7.09 | Sharpe Ratio (0.02) | Expected Return (0.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Sagimet |
Sagimet Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sagimet Biosciences market risk premium is the additional return an investor will receive from holding Sagimet Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sagimet Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sagimet Biosciences' performance over market.| α | -0.26 | β | -0.3 |
Sagimet Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Sagimet Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Sagimet Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Sagimet Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Sagimet Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sagimet Biosciences shares will generate the highest return on investment. By understating and applying Sagimet Biosciences stock market price indicators, traders can identify Sagimet Biosciences position entry and exit signals to maximize returns.
Sagimet Biosciences Return and Market Media
The median price of Sagimet Biosciences for the period between Sun, Dec 29, 2024 and Sat, Mar 29, 2025 is 4.17 with a coefficient of variation of 14.27. The daily time series for the period is distributed with a sample standard deviation of 0.61, arithmetic mean of 4.3, and mean deviation of 0.48. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Sagimet Biosciences SWOT analysis promising NASH drug faces funding hurdles - Investing.com | 01/13/2025 |
2 | Acquisition by Thierry Chauche of 17000 shares of Sagimet Biosciences subject to Rule 16b-3 | 02/06/2025 |
3 | Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... | 02/19/2025 |
4 | Is Sagimet Biosciences Inc. the Best Get Rich Quick Stock to Invest In | 02/25/2025 |
5 | Acquisition by Parsey Merdad of 51459 shares of Sagimet Biosciences at 4.64 subject to Rule 16b-3 | 03/07/2025 |
6 | Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne | 03/11/2025 |
7 | Sagimet Biosciences Issues Earnings Results | 03/13/2025 |
8 | Acquisition by Phillips Anne M. of 113895 shares of Sagimet Biosciences at 3.48 subject to Rule 16b-3 | 03/14/2025 |
9 | Acquisition by David Happel of 116000 shares of Sagimet Biosciences subject to Rule 16b-3 | 03/20/2025 |
About Sagimet Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sagimet or other stocks. Alpha measures the amount that position in Sagimet Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Interest Debt Per Share | 0.002488 | 0.002364 |
| Revenue Per Share | 0.17 | 0.15 |
Sagimet Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Sagimet Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sagimet Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Sagimet Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Sagimet Biosciences. Please utilize our Beneish M Score to check the likelihood of Sagimet Biosciences' management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Sagimet Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.